Alcohol use disorder psychedelic and ketamine research trials
Data as of 11 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
39 registered studies are counted for alcohol use disorder. By compound: 20 psilocybin, 4 MDMA, 1 LSD, 1 DMT, 14 ketamine and 1 ibogaine. By registry status: 11 recruiting, 3 not yet recruiting, 5 active, not recruiting, 13 completed, 1 withdrawn and 6 status not reported. By phase: 1 early phase 1, 6 phase 1, 27 phase 2, 2 phase 3, 2 not applicable and 1 not reported. Reported start years run from 2012 (earliest) to 2026 (latest).
Studies are matched when the title names alcohol use disorder, alcohol dependence, alcohol abuse, alcoholism or alcohol relapse. Drug-interaction studies that merely give alcohol to volunteers are not matched. Studies are matched by keyword on the title as registered, so a study can be missed and a study that mentions the condition only in passing can be included. A study tagged with more than one compound is counted under each compound. Ketamine studies are counted only when PsychoactiveMap classifies them as psychiatric research; anaesthesia, sedation and pain studies are left out.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
At a glance
- 39 registered studies are counted on this page.
By compound
| Compound hub | Studies |
|---|---|
| Psilocybin | 20 |
| MDMA | 4 |
| LSD | 1 |
| DMT | 1 |
| Ketamine | 14 |
| Ibogaine | 1 |
By registry status
| Status | Studies | Share |
|---|---|---|
| Recruiting | 11 | 28% |
| Not yet recruiting | 3 | 8% |
| Active, not recruiting | 5 | 13% |
| Completed | 13 | 33% |
| Withdrawn | 1 | 3% |
| Status not reported | 6 | 15% |
By phase
| Phase | Studies | Share |
|---|---|---|
| Early Phase 1 | 1 | 3% |
| Phase 1 | 6 | 15% |
| Phase 2 | 27 | 69% |
| Phase 3 | 2 | 5% |
| Not applicable | 2 | 5% |
| Not reported | 1 | 3% |
Countries
Country is taken from the study's linked research site. 2 of 39 records have no country on file. The top 10 countries are shown.
| Country | Studies | Share |
|---|---|---|
| United States | 19 | 49% |
| Canada | 4 | 10% |
| Australia | 3 | 8% |
| Switzerland | 3 | 8% |
| France | 2 | 5% |
| United Kingdom | 2 | 5% |
| Belgium | 1 | 3% |
| Brazil | 1 | 3% |
| Germany | 1 | 3% |
| Denmark | 1 | 3% |
When studies started
| Start year | Studies |
|---|---|
| 2024 to 2026 | 20 |
| 2020 to 2023 | 10 |
| 2015 to 2019 | 5 |
| 2010 to 2014 | 4 |
Study design
- 38 interventional and 1 observational studies.
- Median planned or actual enrolment is 42 participants (range 5 to 200, across 38 records that report it).
Registered studies
All counted studies, newest start first. The order is not a ranking and says nothing about quality. Titles are quoted from the registry. Each ID links to its own ClinicalTrials.gov record, which has the eligibility criteria and contacts.
| Title as registered | Registry ID | Status | Phase | Start | Compound |
|---|---|---|---|---|---|
| Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive Symptoms | NCT07638553 | Recruiting | Phase 3 | 2026-06-01 | Psilocybin |
| Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder | NCT07296094 | Not yet recruiting | Phase 2 | 2026-05-01 | Psilocybin |
| MDMA-Assisted Therapy for Veterans With PTSD and Alcohol Use Disorder | NCT07118839 | Recruiting | Phase 2 | 2026-04-15 | MDMA |
| Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use Disorder | NCT07405606 | Not yet recruiting | Phase 2 | 2026-03-01 | Psilocybin |
| Ketamine-Enhanced Therapy for Individuals With Alcohol Use Disorder and Depression: A Pilot Study (KET-DUAL) | NCT07247370 | Not yet recruiting | Phase 1 | 2025-12-10 | Ketamine |
| Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for AUD | NCT06349083 | Recruiting | Phase 2 | 2025-08-26 | Psilocybin |
| The Potential Therapeutic Effects of Psychedelic, N, N-dimethyltryptamine (DMT), on Alcohol Use Disorder (AUD) | NCT06070649 | Recruiting | Phase 1 | 2025-08-04 | DMT |
| Psilocybin or Ketamine for Alcohol Use Disorder: An Active Comparator Trial | NCT06405607 | Recruiting | Phase 2 | 2025-06-12 | Psilocybin, Ketamine |
| Psilocybin With Psychological Support (Psi-PS) for Military Veterans and First Responders With Co-occurring PTSD & Alcohol Use Disorder (AUD) | NCT06853912 | Active, not recruiting | Phase 2 | 2025-06-01 | Psilocybin |
| Ketamine and Neurofeedback as Combined Therapeutic Interventions to Target Glutamatergic Neurotransmission in Alcohol Use Disorder | NCT06969937 | Recruiting | Phase 2 | 2025-06-01 | Ketamine |
| ACT_for Alcohol Use Disorder and Depression | NCT06620276 | Recruiting | Not applicable | 2025-05-01 | Ketamine |
| Observational Pilot Study to Explore the Social and Health Impacts of a New Model of Care in Oregon: Psilocybin Services on Alcoholism | NCT07189988 | Active, not recruiting | Not reported | 2025-03-05 | Psilocybin |
| Ketamine for Combined Depression and Alcohol Use Disorder | NCT06090422 | Recruiting | Phase 1 | 2025-01-01 | Ketamine |
| Psilocybin-assisted Therapy for Alcohol Use Disorder | NCT06444243 | Status not reported | Phase 2 | 2024-09-01 | Psilocybin |
| LSD Treatment for Persons With Alcohol Use Disorder | NCT05474989 | Recruiting | Phase 2 | 2024-06-01 | LSD |
| Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder | NCT05995769 | Recruiting | Phase 2 | 2024-03-20 | Psilocybin |
| Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder | NCT06160232 | Status not reported | Phase 2 | 2024-02-15 | Psilocybin |
| MDMA for AUD/PTSD Comorbidity | NCT05943665 | Completed | Phase 2 | 2024-02-06 | MDMA |
| Psilocybin in Alcohol Use Disorder With Comorbid Depression | NCT06235411 | Completed | Not applicable | 2024-02-05 | Psilocybin |
| Psilocybin-Assisted vs Ketamine-Assisted Psychotherapy for Alcohol Use Disorder | NCT05421065 | Active, not recruiting | Phase 2 | 2024-02-02 | Psilocybin, Ketamine |
| MDMA-assisted Prolonged Exposure Therapy for Comorbid Alcohol Use Disorder and Post-traumatic Stress Disorder | NCT05709353 | Status not reported | Phase 2 | 2023-09-19 | MDMA |
| Psilocybin-assisted Therapy for Treatment of Alcohol Use Disorder | NCT05416229 | Completed | Phase 2 | 2023-09-01 | Psilocybin |
| Ketamine for the Treatment for Alcohol Use Disorder in the ED | NCT05661669 | Withdrawn | Phase 2 | 2023-09-01 | Ketamine |
| Psilocybin for Treatment of Alcohol Use Disorder: a Feasibility Study | NCT04718792 | Status not reported | Phase 2 | 2023-02-09 | Psilocybin |
| Ibogaine in the Treatment of Alcoholism: an Open-label Escalating-dose Trial | NCT03380728 | Completed | Phase 2 | 2022-10-30 | Ibogaine |
| Psilocybin-Assisted Psychotherapy in Adults With Alcohol Use Disorder (AUD) | NCT05646303 | Status not reported | Phase 2 | 2022-05-02 | Psilocybin |
| Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use Disorder | NCT04620759 | Active, not recruiting | Phase 2 | 2021-04-14 | Psilocybin |
| Pilot Trial of Visual Healing® in Psilocybin-assisted Therapy for Alcohol Use Disorder | NCT04410913 | Active, not recruiting | Phase 2 | 2021-02-18 | Psilocybin |
| Inpatient Single Dose Interventions for Alcohol Use Disorder | NCT04562779 | Completed | Early Phase 1 | 2021-01-19 | Ketamine |
| Clinical and Mechanistic Effects of Psilocybin in Alcohol Addicted Patients | NCT04141501 | Completed | Phase 2 | 2020-06-08 | Psilocybin |
| Trial of the Rapid Antisuicidal Effects of Intranasal Ketamine in Comorbid Depression and Alcohol Abuse | NCT03539887 | Completed | Phase 3 | 2018-05-01 | Ketamine |
| Bristol Imperial MDMA in Alcoholism Study | NCT04158778 | Status not reported | Phase 1 | 2018-04-18 | MDMA |
| Ketamine for Reduction of Alcoholic Relapse | NCT02649231 | Completed | Phase 2 | 2016-10-01 | Ketamine |
| Naltrexone Plus Ketamine for the Rapid Treatment of Major Depressive Disorder and Alcohol Use Disorder | NCT03658330 | Completed | Phase 2 | 2016-05-01 | Ketamine |
| Ketamine for the Rapid Treatment of Major Depressive Disorder and Alcohol Use Disorder | NCT02461927 | Completed | Phase 1 | 2015-01-01 | Ketamine |
| A Double-Blind Trial of Psilocybin-Assisted Treatment of Alcohol Dependence | NCT02061293 | Completed | Phase 2 | 2014-06-01 | Psilocybin |
| Ketamine Alcohol (in Treatment-Resistant Depression) | NCT02122562 | Recruiting | Phase 2 | 2014-04-23 | Ketamine |
| Ketamine for Depression and Alcohol Dependence | NCT01551329 | Completed | Phase 1 | 2012-03-01 | Ketamine |
| Effects and Therapeutic Potential of Psilocybin in Alcohol Dependence | NCT01534494 | Completed | Phase 2 | 2012-01-01 | Psilocybin |
About this data
Compound tags come from automated matching of the registry search term and have not been checked record by record. Counts are of registered studies, not of people, results or approvals. A registry listing is not evidence of safety, benefit or results.
Substance hubs for these compounds
Psilocybin | MDMA | LSD | DMT | Ketamine | Ibogaine
Other condition hubs
Depression | Treatment-resistant depression | Bipolar disorder | Post-traumatic stress disorder | Opioid use disorder | Tobacco and nicotine use | Cocaine and methamphetamine use | Anxiety | Cancer and end-of-life distress | Obsessive-compulsive disorder | Eating disorders | Headache and migraine | Chronic pain | Suicidal ideation and suicide risk